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Unlike several tumor suppressor genes, whose 
inactivation is due to deletions or truncating mutations, 
TP53 is most frequently hit by missense mutations 
in its DNA binding domain. Three are the functional 
consequences of these single amino acid substitutions: 
i) abrogation of tumor suppressor activities largely 
due to the inability to recognize wild-type p53 (wtp53) 
consensus sequences on DNA; ii) inhibition of the tumor 
suppressor function of the remaining wtp53 allele because 
of a dominant negative effect; iii) acquisition of new 
oncogenic properties, commonly described as mutant p53 
(mutp53) gain of function, which can actively contribute 
to various aspects of tumor progression [1].
Intensive research in the last decade has definitively 
confirmed  that  mutp53  promotes  the  development 
of aggressive tumors, characterized by a metastatic 
phenotype and high levels of genomic instability [2-
4]. Elegant in vivo studies have suggested that mutp53 
requires additional alterations to exert its gain of function 
activities. Indeed, these properties were shown to be 
associated with mutp53 phosphorylation, suggesting that 
efficient mutp53 function may be triggered by oncogenic 
signaling, similarly to what occurs in the case of wtp53 
[4, 5]. Very recently, we have unveiled a crucial link 
between cancer-related signaling and mutp53 oncogenic 
function: the prolyl isomerase Pin1, which transduces 
proline-directed signaling into mutp53 activation [5].
Our  findings  underline  the  similarities  between 
wtp53 and mutp53 stimulation, although the biological 
outcomes of Pin1 binding and isomerization in either case 
are completely different (Figure 1). Indeed, we and others 
have previously established that Pin1 is essential for 
the proper activation of wtp53 function upon genotoxic 
stress. This enzyme was shown to promote both the 
dissociation of wtp53 from the E3 ubiquitin ligase Mdm2, 
thus increasing its stability, and the recruitment on target 
gene promoters contributing to specific tumor suppressor 
responses such as cell cycle arrest or apoptosis [6-10]. On 
the contrary, the cooperation between Pin1 and mutp53 
gives rise to very opposite effects, since these proteins 
become integrated into a molecular axis supporting 
oncogenic mechanisms [5].
The existence of the Pin1/mutp53 axis was revealed 
in a Li-Fraumeni mouse model, where lack of Pin1 reduced 
tumorigenesis exclusively in mice expressing mutp53. In 
an in vitro model of cell transformation using primary 
fibroblasts derived from those animals, we identified Ras 
signaling as one of the pathways converging on mutp53 
to increase phosphorylation and interaction with Pin1. 
At the same time, lack of Pin1 impaired the ability of 
mutp53 to promote anchorage-independent growth and 
tumorigenicity of H-RasV12 transformed fibroblasts, thus 
indicating that oncogenic signaling per se cannot activate 
mutp53 unless Pin1 is present to bind mutp53 and unleash 
its gain of function properties.
In human breast cancer cells, activation of the Pin1/
mutp53 axis fires oncogenic processes with deleterious 
consequences. In particular, these two proteins cooperate in 
enhancing cell migration and invasion by two independent 
but complementary mechanisms: the inhibition of the 
anti-metastatic factor p63 and the induction of a pro-
aggressiveness transcriptional program. Both require 
mutp53 phosphorylation and interaction with Pin1 and 
result in a substantial reprogramming of gene expression 
that includes repression of tumor suppressor genes, 
comprising several p63 targets, as well as activation of 
genes promoting oncogenic processes. Among the genes 
induced by this axis, we have identified a group of 10 
novel mutp53 direct target genes (that we defined as Pin1/
mutp53 signature), which are regulated by the concerted 
action of these two proteins. Indeed, we demonstrated 
that Pin1 is required for efficient mutp53 recruitment on 
the promoters of this set of genes, suggesting that this 
prolyl isomerase could strengthen the complex between 
mutp53 and transcription factors tethering it on these 
promoters. It is also reasonable to believe that Pin1 might 
sustain expression of these genes by enhancing the ability 
of mutp53 to recruit transcriptional cofactors like the 
acetyl transferase p300, as Pin1 does to increase wtp53 
transcriptional activity [9].
We confirmed the role of some of the 10 signature 
genes as downstream effectors of the Pin1/mutp53 axis, 
showing that they are directly involved in the promotion 
of migration and invasion. Accordingly, all these genes 
are likely to be involved in the progression toward a 
metastatic phenotype in vivo, since their high expression 
levels in tumors of breast cancer patients correlate with 
poor prognosis in terms of both reduced overall survival 
and shorter time to distant metastasis. Furthermore, in 
breast cancer data sets we have now found an intriguing 
association between the Pin1/mutp53 signature and tumor 
grade according to the Nottingham scale (unpublished 
data). Expression of the signature genes was found to be 
lower in G1 cases but high in G3 cases. In addition, it 
is also able to divide G2 cases into two subgroups: the 
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prognosis and the G2-low-level-signature patients having 
better prognosis. G2 tumors have an uncertain prognosis 
and represent the majority of cases [11], therefore, 
expression of the Pin1/mutant p53 signature genes could 
be very useful for proper clinical management of G2 
patients.
The clinical relevance of the Pin1/mutp53 axis is 
further supported by our analysis of a cohort of breast 
cancer patients, in which we could establish that the 
prognostic value of p53 status is conditioned by Pin1 
levels. The correlation between TP53 mutation and poor 
prognosis has been pointed out several years ago, however, 
due to controversial data, the clinical use of TP53 mutation 
as a prognostic marker was delayed [12]. Although 
some inconsistencies may result from the inaccuracy of 
evaluating TP53 mutation indirectly, it is possible that 
TP53 mutation becomes a powerful prognostic marker 
only when combined to the detection of other parameters, 
reflecting the fact that other alterations are required to fully 
activate or cooperate to oncogenic function of mutp53. 
Indeed, our data from breast cancer patients support this 
notion, since only in tumors expressing high Pin1 levels 
the presence of TP53 missense mutations was associated 
to a worse clinical outcome with reduced overall survival 
and early development of metastases.
Our  findings  suggest  that  assembly  of  the  Pin1/
mutp53 axis may be a critical event that tips the 
balance toward tumor aggressiveness with important 
consequences on clinical management. In fact, according 
to Pin1 expression and TP53 mutation or to the levels of 
the 10 signature genes, patients could be actually stratified 
in low- and high-risk groups. Our results not only give a 
significant contribution to the identification of cases not 
effectively responsive to the available therapies, but also 
suggest several potential strategies for the development of 
novel therapies to treat breast tumors or other epithelial 
cancers expressing mutp53 and high Pin1 levels, as for 
example preventing mutp53 phosphorylation and/or 
interaction with Pin1 as well as down-regulating the 10 
signature genes.
Altogether  our  findings  shed  light  on  previously 
unknown details of the molecular mechanisms of tumor 
aggressiveness by revealing the crucial role of Pin1 in 
connecting oncogenic signaling with mutp53 gain of 
function. Nevertheless, several interesting issues worthy 
of further investigation remain. For instance, does Pin1 
impact on other mutp53 associated processes, such as 
genomic instability and chemoresistance? Which are the 
mechanisms underlying transcriptional regulation by 
Pin1 and mutp53? Can Pin1 affect the prognostic value 
of TP53 mutation in other kinds of tumors? Does high 
expression of the 10 signature genes correlate with poor 
prognosis also in those cases? Do these genes mediate 
other aspects of mutp53 gain of function? The answers 
Figure 1: wtp53 versus mutp53 shows similar activation but opposite effects. Upon oncogenic signaling, both wtp53 and 
mutp53 become activated by mechanisms involving several common kinases, such as p38, JNK and others, that modify the same residues. 
These phosphorylations allow Pin1 binding, which leads to full activation of both p53 proteins. Despite these similar steps, the downstream 
events associated to wtp53 or mutp53 are totally different. While the Pin1/wtp53 cooperation triggers tumor suppressor responses including 
apoptosis and cell cycle arrest, the Pin1/mutp53 axis promotes pro-oncogenic properties (such as cell migration and invasion, and possibly 
others like genomic instability, chemoresistance, etc.).
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to these and other questions will help to further elucidate 
mutp53-dependent oncogenic mechanisms and to provide 
the basis for novel therapeutic strategies.
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